La vendita allo scoperto per Luca Mining dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Luca Mining. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Luca Mining (OTC:LUCMF) Azioni, Report sulle vendite allo scoperto

Luca Mining Corp is a Canadian-based mining company engages s the production of base metals and the acquisition, exploration and development of resource properties in Mexico. Luca Mining is currently in commercial production at its 100% owned Campo Morado Mine, processing approximately 2,000 tons per day through the mine milling facilities producing zinc and copper concentrates with gold, silver, and lead as by-products. In addition, Luca owns a 100% interest in the Tahuehueto Project.

Luca Mining Corp

<ul>
<li>Combination creates global platform within the growing sports retail industry, positioned to serve evolving needs of a broader range of consumers</li>
<li>Poised to drive long-term success through innovative store concepts and digital experiences</li>
<li>Foot Locker shareholders can elect to receive either $24.00 in cash or 0.1168&nbsp;shares of DICK'S Sporting Goods common stock for each share of Foot Locker common stock</li>
<li>Transaction expected to be accretive to DICK'S Sporting Goods EPS in the first full fiscal year post-close&nbsp;(excludes one-time costs)</li>
</ul>

News

General

DICK'S Sporting Goods Has Agreed To Acquire Foot Locker. This Transaction Implies An Equity Value Of Approximately $2.4B And An Enterprise Value Of Approximately $2.5B

Canadian Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) lowers FY2025 sales outlook from $7.30 billion-$8.30 billion to $6.10 billion-$7.10 billion vs $7.31 billion estimate.

Guidance

CSIQ

Canadian Solar Lowers FY2025 Sales Guidance from $7.30B-$8.30B to $6.10B-$7.10B vs $7.31B Est

Katapult Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPLT#NASDAQ">KPLT</a>) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.72) by 1.39 percent. This is a 417.39 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $71.95 million which beat the analyst consensus estimate of $71.80 million by 0.20 percent. This is a 10.58 percent increase over sales of $65.06 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

KPLT

Katapult Holdings Q1 Adj. EPS $(0.73) Misses $(0.72) Estimate, Sales $71.95M Beat $71.80M Estimate

Xunlei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNET#NASDAQ">XNET</a>) sees Q2 sales of $91.000 million-$96.000 million.

XNET

Xunlei Sees Q2 Sales $91.000M-$96.000M

Canadian Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) sees Q2 sales of $1.900 billion-$2.100 billion vs $1.76 billion analyst estimate.

Canadian Solar Sees Q2 Sales $1.900B-$2.100B vs $1.76B Est

Vecima Networks (TSX:<a class="ticker" href="https://www.benzinga.com/stock/VCM#TSX">VCM</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.09 by 77.78 percent. This is a 93.55 percent decrease over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $63.98 million which missed the analyst consensus estimate of $72.89 million by 12.23 percent. This is a 20.16 percent decrease over sales of $80.14 million the same period last year.

TSX:VCM

Vecima Networks Q3 Adj. EPS $0.02 Misses $0.09 Estimate, Sales $63.98M Miss $72.89M Estimate

Canadian Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.10) by 2.73 percent. This is a 663.16 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $1.20 billion which beat the analyst consensus estimate of $1.10 billion by 9.19 percent. This is a 10.80 percent decrease over sales of $1.34 billion the same period last year.

Canadian Solar Q1 Adj. EPS $(1.07) Beats $(1.10) Estimate, Sales $1.20B Beat $1.10B Estimate

Xunlei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNET#NASDAQ">XNET</a>) reported quarterly earnings of $0.00 per share. This is a 94.29 percent decrease over earnings of $0.07 per share from the same period last year. The company reported $88.45 million in sales this quarter. This is a 10.60 percent increase over sales of $79.98 million the same period last year.

Xunlei Q1 Adj. EPS $0.00 Down From $0.07 YoY, Sales $88.45M Up From $79.98M YoY

Calfrac Well Servs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CFW#TSX">CFW</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.05) by 280 percent. This is a 400 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $370.06 million which beat the analyst consensus estimate of $350.00 million by 5.73 percent. This is a 12.11 percent increase over sales of $330.10 million the same period last year.

TSX:CFW

Calfrac Well Servs Q1 EPS $0.09 Beats $(0.05) Estimate, Sales $370.06M Beat $350.00M Estimate

Our board of directors has approved a two-part dividend in the total amount of US$0.25 per ordinary share or US$2.00 per ADS comprised of (i) an annual regular cash dividend for fiscal year 2025 in the amount of US$0.13125 per ordinary share or US$1.05 per ADS, and (ii) a one-time extraordinary cash dividend as a distribution of proceeds from disposition of certain businesses and financial investments in the amount of US$0.11875 per ordinary share or US$0.95 per ADS, in each case payable in U.S. dollars, to holders of ordinary shares and holders of ADSs, as of the close of business on June 12, 2025, Hong Kong Time and New York Time, respectively. The aggregate amount of the dividend will be approximately US$4.6 billion.&nbsp;

Dividends

BABA

Alibaba Declares $2.00 Per ADS Dividend, Including $0.95 One-Time Payout From Asset Sales

Macro Economic Events

Econ #s

Economics

Eurozone Industrial Production (MoM) For March 2.6% Vs. 1.9% Est.; 1.1% Prior

Eurozone Gross Domestic Product (QoQ) Preliminary For Q1 0.3% Vs. 0.4% Est.; 0.2% Prior

Eurozone Gross Domestic Product (YoY) Preliminary For Q1 1.2% Vs. 1.2% Est.; 1.2% Prior

U.K. Labour Productivity For Q4 0.7% Vs. 0.7% Est.; -1.1% Prior

Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) reported quarterly earnings of $1.73 per share which beat the analyst consensus estimate of $1.48 by 16.89 percent. This is a 23.57 percent increase over earnings of $1.40 per share from the same period last year. The company reported quarterly sales of $32.58 billion which missed the analyst consensus estimate of $33.08 billion by 1.50 percent. This is a 6.04 percent increase over sales of $30.73 billion the same period last year.

CORRECTION: Alibaba Group Q4 Adj. EPS $1.73 Beats $1.48 Estimate, Sales $32.58B Miss $33.08B Estimate

U.S. stock futures were lower on Thursday after mostly closing higher on Wednesday. Futures of major benchmark indices were trading lower in premarket.
Wednesday saw a positive momentum in tech stocks led by Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) following the <a href="https://www.benzinga.com/news/large-cap/25/05/45405067/saudi-arabia-bets-big-on-ai-teams-up-with-aws-and-nvidia">deals with Saudi Arabia</a>, strong earnings from Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) and CoreWeave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>). 
Nvidia CEO Jensen Huang, who last year sparked &#8220;Jensanity&#8221; among attendees, will headline this year&#8217;s <a href="https://www.benzinga.com/media/25/05/45426637/nvidia-ceo-jensen-huang-expected-to-unveil-new-ai-alliances-at-computex-2025-as-geopolitical-pressures-persist-over-tech-sector">annual Computex trade show</a>, which will run from May 20–23 in Taipei, reported Reuters. His keynote is expected to spotlight Nvidia&#8217;s deepening partnerships with Taiwanese firms like Foxconn and Quanta. 
Investors assessed the economic impacts of a tariff pause with China and await the Producer Price Index data slated to be released today.
The 10-year Treasury bond yielded 4.50% and the two-year bond was at 4.03%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool&#8217;</a>s projections show markets pricing a 91.7% likelihood of the Federal Reserve keeping the current interest rates unchanged in its June meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.42%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.81%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.63%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.35%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Thursday. The SPY was down 0.68% to $583.57, while the QQQ declined 0.87% to $514.18, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Driven by renewed risk appetite after U.S.-China trade negotiation progress, information technology and communication services sectors led gains on Wednesday, bucking the broader negative trend where health care, materials, and real estate stocks saw the biggest losses.
Overall, U.S. stocks settled mixed, with the S&amp;P 500 extending its gains for a third session, up over 4% week-to-date, while the Dow added around 2% and the Nasdaq surged over 6% for the week.
Notably, Nvidia and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) shares climbed significantly. Separately, U.S. mortgage applications saw a modest increase of 1.1%.
The Dow Jones index declined 89 points or 0.21% to 42,051.06, whereas the S&amp;P 500 index rose 0.10% to 5,892.58. Nasdaq Composite ended 0.72% higher at 19,146.81, and the small-cap gauge, Russell 2000, dropped 0.88% to 2,083.80.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.72%</td>
<td>19,146.81</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.10%</td>
<td>5,892.58</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.21%</td>
<td>42,051.06</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.88%</td>
<td>2,083.80</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
According to Scott Wren, the senior global market strategist at Wells Fargo, despite having a bit of a surprise in the outcome in terms of the U.S.-China trade talks, &#8220;The bottom line is that many uncertainties remain.&#8221;
&#8220;The U.S. is in the early stages of trade negotiations. Given that, our guidance is to continue to lean toward higher-quality large- and mid-cap U.S. equities. In fixed income, we favor exposure to investment-grade corporates and essential-service municipal bonds in the three-to-seven-year maturity range,&#8221; he said.
He highlighted that the market bounce back hinged on a variety of factors, including better-than-expected earnings and, particularly, guidance during the first-quarter reporting season as well as expectations that some trade deals would be announced (i.e., last week's U.K. deal).
It also has helped that much of the reported data covering April has so far continued to show U.S. economic resilience, he explained.
Talking about the U.S.-China deal, he said, &#8220;Of course, as always, the devil is in the details, and a deal has not officially been inked. A lot can happen between now and then.&#8221;
Meanwhile, the analysts at BlackRock said that &#8220;We eye opportunities from mega forces,&#8221; adding that &#8220;We still see tariffs causing further contractions in quarterly activity but the cumulative impact may be more limited.&#8221;
&#8220;We still see supply disruptions upping inflation and hitting growth, but also a path to avoiding a U.S. contraction over 2025 as a whole. Mega forces, greater fiscal spending, and higher interest rates are driving select opportunities,&#8221; the note added.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a> 
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Thursday:
<ul class="wp-block-list">
<li>The initial jobless claims data for the week ended May 10 will be out by 8:30 a.m. ET.</li>
</ul>
<ul class="wp-block-list">
<li>April&#8217;s U.S. retail sales, core and headline producer price index, May&#8217;s Empire State manufacturing survey, and Philadelphia Fed manufacturing survey will also be announced at 8:30 a.m. ET.</li>
</ul>
<ul class="wp-block-list">
<li>Fed Chairman Jerome Powell will speak at 8:40 a.m. ET.</li>
</ul>
<ul class="wp-block-list">
<li>April&#8217;s industrial production and capacity utilization will be out by 9:15 a.m. ET.</li>
</ul>
<ul class="wp-block-list">
<li>March&#8217;s business inventories data and May&#8217;s home builder confidence index will be released by 10:00 a.m. ET.</li>
</ul>
<ul class="wp-block-list">
<li>Fed Governor Michael Barr will speak at 2:05 p.m. ET.</li>
<li></li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Alibaba Group Holding Ltd. ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) fell 1.12% as analysts expect it to report quarterly earnings of $1.37 per share on revenue of $33.21 billion, before the opening bell.</li>
</ul>
<ul class="wp-block-list">
<li>Deere &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) was down 0.24% as Wall Street expects it to report earnings before the opening bell. It is expected to post earnings of $5.58 per share on revenue of $10.79 billion.</li>
</ul>
<ul class="wp-block-list">
<li>Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) was 0.43% higher as analysts expect it to report quarterly earnings of 58 cents per share on revenue of $165.88 billion, before the opening bell.</li>
</ul>
<ul class="wp-block-list">
<li>Boot Barn Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) jumped 14.51% despite posting downbeat earnings for its fourth quarter, but issued first-quarter guidance with its midpoint above estimates. The company also announced a $200 million share repurchase program.</li>
</ul>
<ul class="wp-block-list">
<li>Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) advanced 3.44% after posting stronger-than-expected results for its third quarter and raising its fiscal 2025 guidance.</li>
</ul>
<ul class="wp-block-list">
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) was up 0.97% after it inked a record-breaking deal with Qatar Airways of up to 210 planes.</li>
</ul>
<ul class="wp-block-list">
<li>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) declined 4.87% after a report that the Justice Department is investigating the company for possible Medicare fraud.</li>
</ul>
<ul class="wp-block-list">
<li>Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) was 0.93% lower after announcing the redemption of &#8216;series G&#8217; preferred stock.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 3.99% to hover around $60.63 per barrel.
Gold Spot US Dollar fell 0.43% to hover around $3,164.60 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.31% at the 100.7260 level.
Asian markets ended lower on Thursday except India's S&amp;P BSE Sensex and Australia's ASX 200 index. Japan's Nikkei 225, Hong Kong's Hang Seng, South Korea's Kospi, and China&#8217;s CSI 300 indices declined. European markets were mostly lower in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45399940/warren-buffett-shows-how-patience-pays-98-of-his-160-billion-wealth-came-after-turning-65-thanks-the-power-of-compound-interest">Warren Buffett Shows How Patience Pays: 98% Of His $160 Billion Wealth Came After Turning 65, Thanks The Power Of &#8216;Compound Interest&#8217;</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Asia

Equities

Government

Macro Notification

Market Summary

Regulations

Bonds

Broad U.S. Equity ETFs

Emerging Markets

Eurozone

Futures

Commodities

Forex

Treasuries

Federal Reserve

Pre-Market Outlook

Markets

Analyst Ratings

ETFs

BOOT

CRWV

CSCO

NVDA

SCHW

US Stocks Likely To Open Lower After S&P 500's Three-Day Winning Streak: '...Many Uncertainties Remain,' Says Expert

Full-Year 2025: The Company reiterated full-year 2025 non-GAAP total revenue which is expected to be in a range of $2,918 million to $2,938 million, representing 7% year over year growth at the midpoint.
The Company increased full-year 2025 non-GAAP fully diluted earnings per share which is expected to be in a range of $12.28 to $12.48, representing 11% year over year growth at the midpoint.

NICE

NICE Raises FY2025 Adj EPS Guidance from $12.13-$12.33 To $12.28-$12.48 Vs $12.25 Est; Affirms FY2025 Sales Guidance Of $2.918B-$2.938B Vs $2.93B Est

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15081745/Kintor-0515-900x600-1.png" alt="" class="wp-image-12987" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15081745/Kintor-0515-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15081745/Kintor-0515-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15081745/Kintor-0515-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The cash-strapped biotech has begun generating its first revenue from over-the-counter cosmetic treatments, as it pivots away from its original oncology drugs
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Kintor Pharma is shifting from its origins as a cancer drug specialist with its latest two products for freckle-removing and hair loss treatments</li>
<li>The company has generated its first revenue from over-the-counter cosmetic treatments, but is also continuing clinical trials for its hair loss drug</li>
</ul>
Talk about cosmetic makeovers.
When&nbsp;Kintor Pharmaceutical Ltd.&nbsp;(9939.HK) made its Hong Kong IPO in May 2020, the Suzhou-based biotech firm had two potential winners in its pipeline, with clinical trials underway for its cancer and hair-loss treatments. The company was developing proxalutamide for treatment of late-stage prostate cancer, forecasting the China market for the drug could be worth an estimated 21.3 billion yuan ($2.95 billion) by 2025. It also had big hopes for a hair loss drug in development, hoping to enter a market dominated by&nbsp;Johnson &amp; Johnson's&nbsp;(JNJ.US) minoxidil and&nbsp;Merck &amp; Co.'s&nbsp;(MRK.US) finasteride, tapping into a Chinese hair loss market worth 3.1 billion yuan, according to its prospectus.
Fast forward to the present, when the company's approach is undergoing a big shift. Kintor has given up on proxalutamide. What's more the company's&nbsp;<a href="https://staticpacific.blob.core.windows.net/press-releases-attachments/3558273/HKEX-EPS_20250429_11653395_0.PDF">latest annual report</a>&nbsp;for 2024, released in April, shows it has virtually shut down its R&amp;D division for oncology research.
Its current direction is reflected in a more recent&nbsp;<a href="https://staticpacific.blob.core.windows.net/press-releases-attachments/3558273/HKEX-EPS_20250429_11653395_0.PDF">announcement</a>&nbsp;last week, where it disclosed that it has begun to commercialize KT-939, a "functional raw material" for skin whitening and freckle-removing cosmetics. According to data from the China Association of Fragrance Flavor and Cosmetic Industries, cited by Kintor, the global market for such cosmetic materials was worth $50 billion in 2023 and is expected to rise to $60 billion by 2030.
Sales of such products in China were worth 61.9 billion yuan in 2023, Kintor said, citing the association's data. "In the multi-layer layout of the cosmetic raw material market, functional raw material is its core composition," the company said.
Shares of Kintor briefly jumped by 8% the day after last week's announcement, though they later gave back most of that to close up less than 1%. The announcement seemed to confirm Kintor's turn away from the marathon exercise of pushing drugs through clinical trials required to receive regulatory approval.
In addition to KT-939, Kintor is also working on KX-826, a hair loss treatment. It already sells KX-826 in an over-the-counter product called Koshiné, and is also working on clinical trials that, if successful, would give the treatment more credibility as a prescription drug.
In 2024, the company recorded its first revenue of 5 million yuan from Koshiné, whose web page describes the treatment a "cosmetic brand." KX-826 is also currently undergoing clinical trials for treatment of androgenic alopecia (AGA), a type of hair loss that can affect both men and women.
On May 2, the company&nbsp;<a href="https://staticpacific.blob.core.windows.net/press-releases-attachments/3559595/HKEX-EPS_20250502_11658701_0.PDF">announced</a>&nbsp;that a clinical observational study for KX-826, used in combination with minoxidil, for treatment of AGA had reached its "primary endpoint," paving the way for the design of new trials. The results were positive but not exactly huge cause for celebration, saying the study showed a slight advantage to a group that received the combined minoxidil and KX-826 treatment, compared with another group just receiving minoxidil.
<h4 class="wp-block-heading">Dwindling cash</h4>
How the company will fund an envisioned phase three trial for the minoxidil and KX-826 combination, potentially involving thousands of volunteers, is another question. Kintor has been burning through cash for years and is unlikely to attract much interest from investors if it tries to raise new funds by issuing new shares. At the end of last year, it had just 147.4 million yuan in cash, down sharply from 456.3 million yuan at the end of 2023.
Regulatory approval for KX-826 as a prescription drug treatment would put Kintor in the big leagues with only two global competitors. But such approval is by no means guaranteed. For now, according to its annual report, the company is focusing on less capital-intensive cosmetic products. It has offered six such products, including Koshiné, as well as an acne cream based on KX-826 and a whitening essence and lotion based on KT-939, since the beginning of 2025.
The company is using popular social media channels, including Tmall, JD.com, Douyin and Xiaohongshu in China, and Amazon.com internationally, together with its own online sales platform to market the over-the-counter cosmetic treatments. Needless to say, both cosmetic hair loss and whitening products have numerous competitors in both China and globally in the lightly regulated over-the-counter market, and it's not clear what competitive advantage Kintor's products would have.
While its revenue from over-the-counter treatments is still quite small, a more telling number was the 91.7% decrease in Kintor's R&amp;D costs from 938.9 million yuan in 2023 to just 78.1 million yuan last year, reflecting its transition into less cost-intensive cosmetic treatments. That helped the company pare its annual loss by 85.4% to 155 million yuan last year from 1 billion yuan in 2023. The company attributed the big drop in R&amp;D spending to its "increasing focus on investments in core dermatology pipelines KX-826 and GT20029, which have much lower costs compared to oncology pipelines." GT20029 is a topical compound for treatment of AGA.
In jumping into the non-prescription hair loss market, Kintor is joining an increasingly crowded field whose members include&nbsp;Cutia Therapeutics&nbsp;(2487.HK)and&nbsp;Yonghe Medical&nbsp;(2279.HK). Shares of Cutia, which sells a spray for AGA called CU-40102, are down 72% from their June 2023 IPO, while shares of Yonghe Medical, which provides hair transplants and restoration, are down nearly 93% from their market debut at the end of 2021.
Kintor is in the same ballpark, with its shares now down more than 90% from their IPO price. The stock has also defied the broader market for drug stocks, down 2.7% over the last year compared with a 16.5% rise over that time for the Hang Seng Health Care Index.

Biotech

Opinion

Trading Ideas

From Cancer Drugs To Cosmetics: A Cash-strapped Company's Makeover Story

Second-Quarter 2025: Second-quarter 2025 non-GAAP total revenue is expected to be in a range of $709 million to $719 million, representing 7% year over year growth at the midpoint.
Second-quarter 2025 non-GAAP fully diluted earnings per share is expected to be in a range of $2.93 to $3.03, representing 13% year over year growth at the midpoint

NICE Sees Q2 Adj EPS $2.93-$3.03 Vs $2.97 Est; Sees Sales $709M-$719M Vs $715.41M Est

BIRK

Birkenstock Sees Fiscal 2025 Revenue Growth At The High-end Of Previous Guidance (15-17% In Constant Currency) And Is Increasing Its Adjusted EBITDA Margin Guidance To 31.3-31.8%, 50 Basis Points Above Previous Guidance, Implying An Adjusted EBITDA Target Of €660M-€670M

Small Cap

Press Releases

LUCA MINING ANNOUNCES COMMERCIAL PRODUCTION AT TAHUEHUETO AND PROVIDES 2025 PRODUCTION GUIDANCE

LUCA REPORTS RESULTS FOR FIRST DRILL HOLES AT CAMPO MORADO IN OVER TEN YEARS AND CELEBRATES THE MILESTONE OF ONE MILLION HOURS WITHOUT LOST-TIME INJURY AT CAMPO MORADO OPERATIONS

LUCA 2024 YEAR-END RESULTS HIGHLIGHT TRANSFORMATIVE GROWTH AND ACHIEVEMENT

LUCA APPOINTS RAMON MENDOZA INTERIM COO

LUCA'S CASH BALANCE SURGES TO US$21 MILLION THROUGH WARRANT EXERCISE AND CASH FLOW

Metals & Mining Virtual Investor Conference Agenda Announced for May 6-8th

LUCA DISCOVERS MULTIPLE NEW HIGH-GRADE ORE SHOOTS AT TAHUEHUETO MINE, DURANGO, MEXICO

Metals and Mining Virtual Investor Conference: Presentations Now Available for Online Viewing

LUCA DRILLS 3.8m of 12.54 g/t AuEq AS PART OF ONGOING UNDERGROUND DRILL PROGRAM AT CAMPO MORADO

With Forecasts Hitting $4,000 to $6,000, Gold Mining Sector Sees Renewed Investor Focus

Comments

Luca Mining

Vendite allo scoperto

Luca Mining (OTC:LUCMF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO